Amgen Inc stock faces institutional selling pressure amid mixed 13F filings and dividend stability

Institutional investors like Nordea and Sarasin trimmed Amgen Inc stakes in Q4 2025 per recent SEC 13F disclosures (ISIN: US0311621009). Amid biotech sector scrutiny, the NASDAQ:AMGN shares hover around recent levels while dividend yield remains attractive at roughly 2.9%. DACH investors eye pipeline resilience.

Amgen Inc, the Thousand Oaks-based biotech leader, is drawing attention from institutional investors through recent 13F filings revealing stake adjustments in the fourth quarter of 2025. Major players including Nordea Investment Management AB sold 273,268 shares, cutting their position by 9.5%, while Sarasin & Partners LLP trimmed 4,482 shares by 0.7%. These moves, disclosed on March 22, 2026, signal cautious repositioning amid broader biotech volatility. For DACH investors, this highlights opportunities in a high-dividend stock with robust earnings, but warrants scrutiny of pipeline catalysts versus competitive pressures.

As of: 23.03.2026

By Dr. Elena Voss, Senior Biotech Equity Analyst – Tracking Amgen's oncology and rare disease portfolio shifts for European investors navigating US biotech exposure.

Recent Institutional Moves Signal Sector Caution

Nordea Investment Management AB's sale leaves it with 2,601,135 Amgen shares, valued at about $851.9 million at quarter-end, representing 0.7% of its portfolio. This 9.5% reduction underscores selective trimming in large-cap biotech holdings. Sarasin & Partners now holds shares worth around $214.6 million after its minor cut, maintaining a notable but adjusted exposure.

These filings coincide with other activity: Wealth Enhancement Advisory Services reduced by 5.6%, selling 22,365 shares to own 378,221 valued at $125.9 million. Conversely, Concurrent Investment Advisors boosted its stake 46.54% by adding 12,365 shares to reach 38,933 worth $12.7 million. Mixed signals reflect divergent views on Amgen's valuation post-earnings.

Amgen shares on NASDAQ opened around $347.80 recently, down 0.6% in early trading, within a 52-week range of $261.43 to $391.29. Market cap stands at $187.49 billion with a P/E of 24.44. Institutional adjustments often precede sentiment shifts, making this timely for DACH portfolios seeking US biotech balance.

Dividend Strength Anchors Investor Interest

Amgen reaffirmed its shareholder commitment with a quarterly dividend of $2.52 per share, annualizing to $10.08 and yielding approximately 2.9% based on recent prices. Record date is May 15, 2026, with payment on June 5, 2026, and a payout ratio of 44%. This reliable income stream appeals to DACH investors favoring defensive biotech plays amid volatility.

The dividend follows strong Q4 2025 earnings released February 3, 2026, where EPS hit $5.29 against expectations of lower figures, revenue reached $9.87 billion beating $9.47 billion forecasts. Return on equity at 102.03% and net margin of 20.98% underscore operational efficiency. Balance sheet metrics include debt-to-equity of 6.31, quick ratio 0.90, current ratio 1.14.

For German-speaking investors, Amgen's yield compares favorably to European pharma peers, offering currency-hedged income potential through NASDAQ:AMGN ADRs or ETFs. Stability here contrasts with institutional sales, suggesting long-term holders may view dips as entry points.

Pipeline Progress in Oncology and Beyond

Amgen's therapeutic focus spans oncology with Kyprolis from the Onyx acquisition, alongside recent launches like Lumakras for lung cancer. Repatha addresses cholesterol, Aimovig migraines, Tezspire asthma. The 2023 Horizon Therapeutics buy added rare disease assets including Tepezza for thyroid eye disease.

These franchises drive revenue growth, with Q4 beats signaling launch traction. Oncology remains core, bolstered by blockbuster potential in targeted therapies. For DACH markets, Amgen's European approvals and reimbursement paths enhance relevance, particularly in high-prevalence areas like cardiovascular and respiratory diseases.

Pipeline depth mitigates patent cliffs on legacy products like Enbrel and Prolia. Investors monitor readout timelines for next-gen modalities, balancing R&D spend against free cash flow supporting dividends and buybacks.

Risks from Institutional Trimming and Valuation

Multiple trims by Nordea, Sarasin, and Wealth Enhancement raise questions on near-term sentiment. While Concurrent added, net selling by larger funds could pressure shares if replicated. Truist Financial's modest target hike to $319 with 'hold' rating reflects tempered optimism.

Biotech risks include pipeline failures, regulatory hurdles, and competition from biosimilars. Amgen's beta of -0.01 indicates low volatility, but debt levels merit watch amid interest rate paths. 50-day MA at $359.42 above recent opens suggests potential mean reversion, yet 200-day at $316.58 flags longer caution.

DACH investors face FX risk with USD exposure, plus EU regulatory divergences. Qualitative assessment: balanced risk-reward if earnings momentum persists, but sales signal warrants pause.

DACH Investor Relevance in Portfolio Context

German, Austrian, and Swiss investors increasingly allocate to US biotech for growth and yield, with Amgen fitting dividend aristocrat profiles. NASDAQ:AMGN trades qualify for many depot structures, offering tax-efficient income via withholding credits.

Amid ECB policy and regional pharma consolidation, Amgen provides diversification from Eurozone cyclicals. Recent filings highlight monitoring opportunities, as institutional caution often precedes retail entry. Pair with hedges against USD weakness for optimal positioning.

European funds like those from DACH managers hold Amgen, per public disclosures, underscoring peer interest. Focus on dividend reinvestment compounds appeal in low-yield environments.

Strategic Outlook and Market Positioning

Amgen's scale – one of world's largest biotechs – supports M&A firepower, as seen in Horizon deal. Focus on inflammation, oncology, and rare diseases positions for demographic tailwinds. DACH relevance grows with aging populations driving demand for chronic therapies.

Guidance post-earnings implies sustained growth, with margins resilient despite R&D intensity. Institutional mixed bag reflects debate on premium valuation, yet dividend covers provide floor. Watch Q1 2026 for pipeline updates.

For conservative DACH strategies, Amgen slots into core holdings, blending income with biotech upside minus small-cap risks.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.